Genesee Valley Trust Co. Buys Shares of 11,755 Zoetis Inc (ZTS)

Genesee Valley Trust Co. bought a new stake in Zoetis Inc (NYSE:ZTS) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,755 shares of the company’s stock, valued at approximately $847,000.

Several other hedge funds have also recently modified their holdings of the company. Wilbanks Smith & Thomas Asset Management LLC raised its holdings in shares of Zoetis by 1.8% in the 2nd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 5,682 shares of the company’s stock valued at $354,000 after purchasing an additional 98 shares during the period. Scotia Capital Inc. raised its holdings in shares of Zoetis by 1.5% in the 2nd quarter. Scotia Capital Inc. now owns 9,628 shares of the company’s stock valued at $601,000 after purchasing an additional 142 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in shares of Zoetis by 7.3% in the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after purchasing an additional 401 shares during the period. Sandy Spring Bank raised its holdings in shares of Zoetis by 2.3% in the 4th quarter. Sandy Spring Bank now owns 31,018 shares of the company’s stock valued at $2,235,000 after purchasing an additional 708 shares during the period. Finally, Wendell David Associates Inc. raised its holdings in shares of Zoetis by 8.4% in the 4th quarter. Wendell David Associates Inc. now owns 10,300 shares of the company’s stock valued at $742,000 after purchasing an additional 800 shares during the period. 93.73% of the stock is currently owned by institutional investors.

A number of brokerages have recently issued reports on ZTS. BMO Capital Markets set a $78.00 target price on shares of Zoetis and gave the company a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $86.00 target price on shares of Zoetis in a report on Thursday, January 18th. Jefferies Group reaffirmed a “buy” rating and issued a $89.00 target price on shares of Zoetis in a report on Tuesday, January 16th. Zacks Investment Research cut shares of Zoetis from a “hold” rating to a “sell” rating and set a $83.00 target price on the stock. in a report on Saturday, January 13th. Finally, Cantor Fitzgerald set a $85.00 target price on shares of Zoetis and gave the company a “buy” rating in a report on Thursday, January 11th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $73.72.

Zoetis Inc (ZTS) opened at $73.86 on Thursday. Zoetis Inc has a 52-week low of $52.00 and a 52-week high of $80.13. The stock has a market cap of $35,703.61, a P/E ratio of 38.87, a price-to-earnings-growth ratio of 1.62 and a beta of 1.06. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.68%. The ex-dividend date of this dividend is Thursday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio is presently 26.32%.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/08/genesee-valley-trust-co-buys-shares-of-11755-zoetis-inc-zts.html.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit